A&G Pharmaceutical
Theranostics company focused on developing monoclonal antibodies against cancer-specific targets and linked companion diagnostics. Uses a proprietary biomarker discovery platform to identify tumor-specific biomarkers and pursues co-development of targeted therapeutics and diagnostic assays to enable earlier detection, patient selection, monitoring of treatment response, and prediction of recurrence in oncology.
Industries
Nr. of Employees
small (1-50)
A&G Pharmaceutical
Patents
Materials and methods for the development of an antigen-specific immune non-responsiveness state
US-11801287-B2
View DetailsMonoclonal antibodies and conjugates against prostaglandin F2 receptor inhibitor and uses thereof
US-11555074-B2
View DetailsCompositions and methods for restoring sensitivity to treatment with HER2 antagonists
US-7674460-B2
View Details
Materials and methods for the development of an antigen-specific immune non-responsiveness state
US-11801287-B2
View DetailsMonoclonal antibodies and conjugates against prostaglandin F2 receptor inhibitor and uses thereof
US-11555074-B2
View DetailsCompositions and methods for restoring sensitivity to treatment with HER2 antagonists
US-7674460-B2
View DetailsProducts
Monoclonal antibody targeting progranulin (research use)
Monoclonal antibody directed against human progranulin for research use in breast cancer, other cancers, and related diseases.
Monoclonal antibody targeting progranulin (research use)
Monoclonal antibody directed against human progranulin for research use in breast cancer, other cancers, and related diseases.
Services
Discovery of tumor-specific biomarkers using a proprietary biomarker discovery platform to inform diagnostic and therapeutic development.
Development of diagnostic assays designed to detect and monitor cancer-specific biomarkers and enable patient selection for targeted therapies.
Co-development services for linked therapeutic and diagnostic programs to create integrated Rx-Dx product tandems.
Discovery of tumor-specific biomarkers using a proprietary biomarker discovery platform to inform diagnostic and therapeutic development.
Development of diagnostic assays designed to detect and monitor cancer-specific biomarkers and enable patient selection for targeted therapies.
Co-development services for linked therapeutic and diagnostic programs to create integrated Rx-Dx product tandems.
Expertise Areas
- Theranostics (Rx-Dx) co-development
- Monoclonal antibody therapeutics
- Biomarker discovery and validation
- Diagnostic assay development
Key Technologies
- Monoclonal antibody engineering
- Biomarker discovery platforms
- Companion diagnostic assays
- Immunoassays